T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.

Conclusions: Patients unresponsive to SRLs with a lower SST2 receptor expression are more prone to achieve tumor shrinkage during PAS-LAR. Surprisingly, tumor shrinkage is not accompanied by a biochemical response, which is accompanied with a higher T2-signal intensity. PMID: 32375119 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32375119?dopt=Abstract

Source: European Journal of Endocrinology - May 7, 2020 Category: Endocrinology Authors: Coopmans EC, Schneiders JJ, El-Sayed N, Erler NS, Hofland LJ, van der Lely AJ, Petrossians P, Potorac J, Muhammad A, Neggers SJCMM Tags: Eur J Endocrinol Source Type: research

More News: Acromegaly | Endocrinology | Hormones | Study